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This dissertation investigated the biochemical modifications and physiological
changes associated with the phosphorylation of adult rat contractile proteins (Tnl and
TnT) using protein kinase C (PKC) isozymes (a, 6, s, and Q and protein kinase A (PKA).
It was hypothesized that the phosphorylation of adult rat cardiomyocytes by various PKC
isozymes and PKA have specific substrates on myofibrils. It was also hypothesized that
the phosphorylation of adult rat cardiomyocytes by PKC and PKA has alternating
physiological effects on Mg ATPase activity, calcium sensitivity, and rate ofmyocyte
contraction.
Adult rat cardiomyofibrils were phosphorylated in vitro by PKC isozymes and
PKA using [y- P] ATP. PKC isozymes and PKA showed intermolecular specificities in
phosphorylating rat cardiac myofibrils. These results were substantiated by the in situ
phosphorylation of adult rat cardiomyocytes using ^^P. Isolated cardiomyocytes were
incubated with antagonists, agonist, inhibitors, or inducers ofPKC isozymes and PKA
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adrenergic pathways. These treatments resulted in increased and decreased
phosphorylation ofmyofibrillar substrates, consequently supporting the in vitro data that
displayed substrate specificity ofPKC and PKA.
In general, phosphorylation of rat cardiac myofibrils by PKC isozymes (a, 6, e,
and Q and PKA decreased myofibrillar Mg^’^ATPase activity. However, they had diverse
effects on calcium sensitivity. Phosphorylation of cardiomyocytes by PKC and PKA
altered the velocity of contraction. The averages of the velocities were: control
(untreated) -2.60 x 10'^ m/s, isoproterenol-6.00 x 10'^ m/s, phenylephrine- 3.47 x 10'^
m/s, TPA-1.67 x 10'^ m/s, and chlereythrine chloride-2.68 x 10'^ m/s.
In summary, these results revealed that PKC isozymes and PKA phosphorylation
of rat cardiomyofibrils have specific substrates, and alternative biochemical and
physiological effects on cardiac muscle contraction.
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With the rise in heart related illnesses and death, there is an increased need for
research to yield a better understanding of cardiac function. At the close of 2004, the
American Heart Association (AHA) reported that at least 79.4 million people in this
country suffered from some form of cardiovascular disease (Rosamond et al. 2007, e69-
el71). One person in four suffered from some form ofhigh blood pressure, coronary
heart disease, angina pectoris, myocardial infarction, stroke, rheumatic heart disease,
congenital cardiovascular defects, or congestive heart failure. It has also been reported
that heart disease is an equal opportunity killer; affecting all sexes, races, and ages. The
AHA reported that in 2004, the number ofmale deaths from cardiovascular disease was
410,365 (47.1%), and the number of female deaths was 461,152 (52.9%). This is more
than the next 16 causes of death combined. Though men commonly suffer from heart
disease at a younger age than women, more than 50% ofwomen alive today are expected
to perish from cardiovascular disease. One in 3 men can expect to develop
cardiovascular disease before the age of60. For women of the same age, the odds are 1
in 10. As of2007, the AHA also reports that cardiovascular associated diseases are
anticipated to account for approximately 431.8 billion dollars in health care costs.
The goal of this project was to understand the biochemistry and functional
physiology of contractile protein phosphorylation by PKC and PKA. The central
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hypothesis was that in situ phosphorylation of contractile proteins by PKC and PKA
results in alterations in biochemical and physiological phenomena. The involvement of
PKC and PKA phosphorylation of contractile proteins, along with their ability to
decrease Mg ATPase activity and Ca sensitivity, are considered to be vital parameters
in modulating and evaluating cardiac muscle contractility and cardiomyopathy. It is
hoped that the results of this project on the regulation of cardiac function will lead to new
strategies thatwill prove useful in the treatment or deterrence of cardiovascular diseases.
SPECIFIC AIMS
Specific Aim I: To characterize the in vitro phosphorylation of contractile proteins (Tnl
and TnT) in adult rat cardiomyofibrils by PKC isozymes and PKA. It was hypothesized
that PKC isozymes and PKA will display site-specific phosphorylation of contractile
proteins (TnT and Tnl) in adult rat cardiomyofibrils. To investigate this hypothesis, the
following procedures were employed:
A. Surgical removal of adult male rat heart and isolation of cardiomyofibrils.
B. Chromatographic purification ofpan PKC and PKA from living tissue.
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C. Phosphorylation of cardiomyofibrils by PKC isozymes and PKA using [y- P]
ATP.
D. Analysis ofphosphorylated contractile proteins using scintillation counting,
SDS-PAGE, autoradiography, and densitometry.
Specific Aim 2: To determine the modifications in situ phosphorylation of adult male rat
cardiomyocytes using activators, inhibitors, agonists, or antagonists ofPKC isozymes,
PKA, and their respective adrenergic pathways. It was hypothesized that the in situ
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phosphorylation of contractile proteins (TnT and Tnl) in adult rat cardiomyocytes is
modified by activators, inhibitors, agonists, or antagonists ofPKC isozymes, PKA, and
their respective adrenergic pathways. This hypothesis was investigated by the following
procedures:
A. Surgical removal and perfusion ofwhole adult male rat heart.
B. Isolation of ventricular cardiomyocytes and microscopic analysis of viability.
C. In situ phosphorylation of cardiomyocytes using ^^P and treatments with
activators, inhibitors, agonists, or antagonists of PKC isozymes, PKA, and
their respective adrenergic pathways.
D. Analysis of in situ phosphorylated proteins by scintillation counting, SDS-
PAGE, autoradiography, densitometry, graphing, and statistical evaluations.
Specific Aim 3: To determine the physiological changes associated with the
phosphorylation of adult rat cardiomyofibrils with PKC isozymes and PKA. It was
hypothesized that the phosphorylation of adult rat cardiomyofibrils with PKC isozymes
and PKA will have alternating effects on the Mg ATPase activity and calcium
sensitivity. This hypothesis was investigated by using the following procedures:
A. Surgical removal and isolation ofwhole cardiomyofibrils from the heart of an
adult male rat.
B. Enzymatic assays ofMg^"^ATPase activity at various Ca^"^ concentrations.
C. Analysis of data using scintillation counting, graphing, and statistical
evaluations
Specific Aim 4: To determine the mechanical changes associated with the in situ.
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phosphorylation of adult rat cardiomyocytes by PKC isozymes and PKA using activators,
inhibitors, agonists, or antagonists of PKC isozymes, PKA, and their respective
adrenergic pathways. It was hypothesized that the in situ phosphorylation of adult rat
cardiomyocytes by PKC isozymes and PKA using activators, inhibitors, agonists, or
inducers ofPKC isozymes, PKA, and their respective adrenergic pathways will display
alternating effects on the cardiomyocytic contractile velocity. This hypothesis was
investigated by the following procedures:
A. Surgical removal and perfusion ofwhole adult male rat heart.
B. Isolation of ventricular cardiomyocytes and microscopic analysis ofviability.
C. Incubation of cardiomyocytes with activators, inhibitors, agonists, or inducers
ofPKC isozymes, PKA, and their respective adrenergic pathways.
D. Video recording of the cardiomyocyte contractile movements.
E. Measurement of distances and times between cardiomyocyte contractile




The well-known function of the heart involves its contraction and relaxation to
pump essential nutrients contained in the blood throughout the body. The heart is made
up of several muscle cells, termed cardiomyocytes, which work together as one large
muscle. The contraction of the heart is spontaneously initiated by the heart muscle itself
rather than from an external stimulus, a phenomenon known as autorhythmicity.
Autorhythmic cells of the heart, localized at the sinoatrial nodes and purkinje fibers, are
specialized for initiating and conducting the action potentials responsible for contraction
of the contractile cells of the heart. The membrane potential of cardiomyocytes drifts
until a threshold is reached. At this point, the membrane fires and triggers an action
potential. The action potential in the contractile cells travel down transverse tubules (T-
A ■
tubules), simultaneously releasing Ca from the sarcoplasmic reticulum and stimulating
the entry ofCa from the extracellular fluid (ECF). Once the calcium enters the cytosol,
it binds to the troponin C (TnC) (18kD) component of the troponin-tropomyosin
complex. This stimulates an increase in affinity of the actomyosin Mg ATPase
inhibitory component, troponin 1 (Tnl) (23kD), for TnC, while causing a decrease in Tnl
affinity for actin (Ward et al. 2002,41795-41801; Dong et al. 1999, 31382-31390;
Gordon et al. 2000, 853-924). The troponin T (TnT) (37kD) component (bound to TnC,
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Tnl, and tropomyosin (Tm) (33kD)) pulls Tm away from its blocking position between
actin and the myosin head cross bridge. This exposes the Mg^'^ATPase molecules of
actin to the ATP bound molecule of the myosin head cross bridge, resulting in a power
stroke which pulls actin inward along the myosin filament, otherwise known as muscle
contraction.
ADRENERGIC PATHWAYS AND KINASE ACTIVATION
Cardiac muscle contraction may be influenced by the autonomic nervous system.
Epinephrine (from the adrenal gland) and norepinephrine (from the postganglionic
sympathetic nerves) are released in response to stress. Pi- and P2- adrenergic receptors
(located on the surface ofmyocytes) receive these hormones, which pass through a
cascade of signal transduction events that include the guanine nucleotide-binding
regulatory proteins and effector enzyme, adenylate cyclase (Zhu et al. 2005, 507-509;
Kuschel et al. 1999, 22048-22052; Feldman et al. 1993, 27-34). This signaling cascade
results in the production of cyclic AMP, activation of protein kinase A (PKA), and
ultimately the phosphorylation ofmyofibrillar proteins (i.e. the troponin complex) that
are essential to the excitation or inhibition ofmuscle contraction (Zhang et al. 1995,
30773-30780). In chronic heart failure, positive inotropic effects of p-adrenergic
receptor agonists are significantly reduced due to loss of receptor functions (receptor
imcoupling) and reduction in the number of receptors (down regulation) (Wang et al.
2005, H151-H159; Ungerer et al. 1993,454-463).
On the other hand, the a-adrenergic receptor is the means by which the signaling
protein, protein kinase C (PKC) is induced (Price et al. 2002, 9570-9579). It has been
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indicated to play an important role in cardiac function (Puceat et al. 1994,249-268). The
regulation ofcontraction through the a-adrenoreceptor pathway includes the second
messenger diacylglycerol (DAG) and the phosphoinositol (PI) derivative, inositol 1,4,5-
triphosphate (IP3). Certain PKC isozymes are activated by DAG (Pi et al. 1997, 92-100)
while IP3 stimulates the release of sequestered Ca^^ (stored in the sarcoplasmic reticulum
of the muscle cell), which activates Ca^'^-dependent PKC isozymes. These isozymes are
the classical or conventional subtypes (a, Pj, Pj,, and y) and are also phosphatidylserine
(PS)-dependent. Other types of isozymes include the novel subtypes (5, s, r\, and 0) that
are Ca ^"^-independent, but PS/diacylglycerol-dependent, and the atypical subtypes (^, X,
and i) that are PS-dependent, but Ca - and diacylglycerol-independent (Nishizuka 1992,
8808-8814). Effects of PKC on cellular functions depend, therefore, on the properties of
the isozymes. These effects include: (a) cellular and tissue distribution, (b) response to
stimuli, (c) substrate specificity, and (d) activation pathway. Stimulation by aj-
adrenergic agonists causes PKC to translocate into myofibrillar compartments of the
heart (Korzick et al. 2001, H581 - H589; Otani et al. 1992, 22-26; Mochly-Rosen et al.
1992, 693-706; Liu et al. 1989,1105-1110), suggesting that its target substrates are most
likely to be found there. This eventually led to finding the subcellular localization of six
PKC isozymes (a. Pi, Pn, 5, e, and Q in non-stimulated cardiac myocytes and in
myocytes stimulated by noreprinephrine or phorbol 12-myristate 13-acetate (Disatnik et
al. 1994,287-297).
Receptor uncoupling involves phosphorylation of receptor proteins by specific a-
adrenergic receptor kinases. In failing myocardium Ca sensitivity of isometric
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contraction is increased, but PKC and PKA phosphorylation of contractile proteins (Tnl
and TnT) decreases Ca sensitivity (Suematsu et al. 2001, H637-H646; Wolff et al.
1995, 781-789), indicating a regulatory role ofphosphorylation of these proteins in
cardiac function. Several signal transduction defects, such as reduction in cAMP
2+
formation and an altered intracellular Ca handling, have been observed in human
cardiomyopathy (Saucerman and McCulloch 2006, 348-361; Bohm et al. 1994, 1713-
1719). Treatment ofmyofibrils from chronic heart failure with PKA decreases Ca^"^
sensitivity (Hahn et al. 2003, llll-1119;Knowltonetal. 1993,15374-15380). It is
2+
possible that cAMP-dependent PKA and Ca -dependent PKC functions will
consequently be altered in the pathologic heart. Therefore, PKA and PKC
phosphorylation ofTnl and TnT is a vital regulatory parameter for evaluating contractile
processes in the heart.
All the contractile proteins of the heart have been implicated in one or more forms
of cardiomyopathy. For example, familial hypertrophic cardiomyopathy (FHC) has been
linked to modified cardiac TnT (Frey et al. 2006, 29575-29582; Thierfelder et al. 1994,
701-712). A mutation in the splice donor of intron 15 of the TnT gene causes FHC. FHC
has been associated with several mutations in the gene encoding human cardiac troponin I
(HCTnl), in which case a missense mutation in the inhibitory region ofTnl replaces an
arginine residue (position 145) with a glycine and cosegregates with the disease (Lang et
al. 2002, 11670-11678). Recent findings have supported the hypothesis that thin filament
heterogeneity, due to the co-expression ofalternatively spliced cTnT variants, may
desynchronize myocardial contraction and contribute to the pathogenesis and
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pathophysiology of cardiomyopathy and heart failure (Biesiadecki et al. 2002, 50275-
50285). Experiments have shown that in dilated cardiomyopathy and heart failure, the
organization and the amount of contractile proteins (actin, Tnl, TnT, and Tm) suffers
severe disarrangement or lack ofmyofilaments (Venkatraman et al. 2003,41670-41676;
Hein et al. 1994,1291-1306). It has also been reported that mutation on TnT accounts
for about 15% of all cases ofFHC. Findings have shown that in vitro phosphorylation of
contractile components by PKC affect interactions between the thick and thin filament,
displaying an inhibition of Ca ^"^-stimulated Mg^'^ATPase activity and alterations in
calcium sensitivity (Jideama et al. 2006, 1-9; Noland et al. 1995,25445-25454). Though
there have been many advances in the understanding of contractile phosphorylation by
PKC and PKA, few have extended beyond in vitro experiments.
CHAPTER 3
MATERIALS AND METHODS
PREPARATION OF RAT CARDIAC MYOFIBRILS FOR IN VITRO STUDIES
Surgical removal of the heart was performed on adult male Sprague-Dawley
strain rats. The heart was cleaved from the body of the rat by severing the vena cava and
aortic vessels. Myofibrils were extracted from rat ventricular myocardia by detergent
extraction as described by published methods (Murphy et al. 1990,46-49). Rat ventricles
were minced and homogenized in 10-15 mL ofhomogenate buffer (25mM imidazole at
pH 7.0 and 2-mercaptoethanol) on ice. The homogenate solution was diluted (2 fold)
with solution A (60 mM KCl, 30 mM imidazole at pH 7.0, 15 mM mecarptoethanol, and
2.5 mM MgCb) and centrifuged at 10,000 times gravity (g) for 20 minutes in a J2-21
Beckman centrifuge. The pellet was retrieved and resuspended in solution A (5 mL/g)
and centrifuged at 5,000 x g for 10 minutes. The resulting pellet was resuspended in
solution A with 1 mM EGTA and centrifuged at 5,000 x g for 10 minutes. The resulting
pellet was resuspended in solution A with 1% Triton X-100 and centrifuged at 5,000 x g
for 10 minutes. The pellet was resuspended in solution B that contained 60 mM KCl, 30
mM imidazole at pH 7.0, and a protease inhibitor cocktail (O.Olmg/mL leupeptin,
O.Olmg/mL antipain, O.Olmg/mL aprotinin, and O.Olmg/mL pepstatin A). The
resuspended was then centrifuged at 5,000 x g for 10 minutes. The pellet was
resuspended and pelleted in solution B two more times. The resulting pellet was
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resuspended in ice cold ethanol, and centrifuged at 5,000 x g for 10 minutes. The pellet
was resuspended in 50 mL ofpolypropylene and centrifuged at 5,000 x g for 10 minutes.
The pellet was subjected to the same polypropylene resuspention and centrifugation twice
more. The resulting pellet was resuspended in an ice-cold solution consisting of acetone
and the protease inhibitor cocktail for 2 hours.
PURIFICATION AND ASSAY OF KINASE ENZYMES
Pan PKC was purified from bovine brain extracts by DEAE-cellulose and Affi-
Gel Blue chromatography as performed in previously published methods (Uchida et al.
1984,12311-12314). The enzyme was further purified to homogeneity by means of
PCPA affinity chromatography. PKA was purified from bovine heart extracts using
anion-exchange chromatography according to previously published methods (Kuo et al.
1970,79-91). PKC isozymes a, 6, s, and ^ were purchased from Upstate/Millipore
Corporation (Charlottesville. VA, USA). Protein kinase activity was assayed in a 200 pL
(pH 7.5) reaction mixture (0.05 mL PIPES, 0.02mL MgCb, 0.0ImL phosphatidylserine,
0.02 mL ofHlhistone, 0.05 mL distilled water, 0.02 mL of enzyme, 0.02 mL EGTA
(2mM)/ CaCla (5mM), and 0.01 [y^^P] ATP) and incubated for 5 minutes in a 30°C water
bath shaker (ATP was used to initiate the reaction). Phosphatidylserine and diolein were
combined, evaporated under nitrogen, and dispersed in water or 10 mM Tris (pH 7.5) by
sonication (60 Sonic Demembrator, Fisher Scientific) for 2-5 minutes. Reactions were
terminated by the addition of 1 mL of ice cold 5% trichloroacetic acid (TCA) and 0.2 mL
of 0.65%bovine serum albumin (BSA). Precipitated protein was sedimented by
centrifugation, redissolved in 0.5 N NaOH, reprecipitated with stopping solution. This
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was repeated three times and finally counted in a LS6500 Beckman scintillation
spectrometer.
IN VITRO PHOSPHORYLATION OF RAT VENTRICULARMYOFIBRILS
Phosphorylation of rat ventricular myofibrils by classical isozyme PKC-a was
carried out according to published methods (Jideama et al. 1996,23277-23289; Venema
et al. 1993,401-406; Noland et al. 1993, 53-65) using 0.2 mL of the reaction mixture
containing 50 mM Tris/HCl (pH 7.5), 100 mM MgCb^ 25 pg/ml ofPS, 2 pg/ml of
diolein, 100 mM CaCb, 100 mM KCl, 30 mM 2-mercaptoethanol, 10 nM calyculin A, 21
pg ofmyofibrils, and appropriate amounts of enzyme. Phosphorylation ofmyofibrils by
novel (PKC-5 and -e) and atypical (PKC-Q isozymes was performed in the same manner
as classical isozymes, except for omitting the use ofCaC^ in novel reaction mixtures and
CaCl2/diolein in atypical reaction mixtures. Phosphorylation by PKA was carried out in
the same manner as PKC phosphorylation with the exception of 10 mM cyclic AMP
being added as an activator instead ofphospholipid, diolein, and CaCla.
32 6
The reaction was initiated by the addition of 5 pM [y- P] ATP (1-2x10 cpm)
and incubated for 60 minutes at 30^0. It is likely that actomyosin ATPase and PPl may
32
be present in the myofibril preparation, therefore, repeated additions of 5 pM [y- P]
32
ATP were used for stoichiometric phosphorylation. The P- myofibrils were subjected
to direct precipitation with 5% trichloroacetic acid containing tungstate. Bovine serum
albumin was used as a carrier protein during precipitation ofmyofibrils. The
phosphorylation of samples was evaluated by SDS-PAGE, autoradiography, densitometry
(UN-SCAN-ITgeP^ gel and graph digitalizing software from the Silk Scientific
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Corporation (version 6.1)), and liquid scintillation counts.
PROTEIN SEPARATION AND ANALYSIS
Phosphorylated cardiomyofibrils and cardiomyocytes were analyzed by sodium
dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE) as performed by
published methods (Laemmli 1970, 680-685). Phosphorylated proteins were boiled for 5
minutes and loaded in the wells of a 12% SDS-PADE gel with a molecular weight (MW)
marker lane. The proteins and MW markers were separated using a voltage of25mV.
This was followed by staining with Coomassie Blue R-250 (Sigma-Aldrich, USA) and
destaining using a 50% methanol, 10% acetic acid solution. The gel was dried using a
543 BioRad gel dryer. The gels were placed in Kodak cassettes with Kodak BioMax MS
Film (VWR, USA) for varied times based on the strength of the radioisotope as
determined by scintillation counts using a LS6500 Beckman scintillation spectrometer.
The autoradiograph films were exposed using a Kodak M35 XOMAT processor and
further analyzed by ih^UN-SCAN-ITgeV^ gel and graph digitalizing software from
Silk Scientific Corporation (version 6.1) in order to determine the integrated density
values of the bands. Graphs and statistical analysis were formulated by using the
GraphPad Prism® software (version 4.03).
ISOLATION OF RAT CARDIAC MYOCYTES FOR INSITU STUDIES
A modified version of a previously published method was used (Murphy et al. 1990,46-
49). The heart of an adult male Sprague-Dawley strain rat was surgically extracted by
cleaving the vena cava and aortic vessels, and immediately placed in cold HEPES buffer
at pH 7.0 containing 4.9 mM KCl, 137 mM NaCl, 20 mM Hepes, 1.2 mM NaH2P04,15
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mM dextrose, and 1.2 mM MgS04. Perfusion of the heart was conducted by way of the
aorta. The heart was purfused with Earles Balanced Salt Solution (BBSS) (5.4 mM KCl,
116.4mMNaCl, 26.2 mMNaHCOa, 1.0 mM NaH2P04 x H2O, 5.6 mM dextrose, and 1.6
mM MgS04), at 37°C, until the solution eluting from the heart was clear in color. BBSS
was mixed with 1% collagenase B (Worthington Biochemical Corporation) and
O.Olmg/mL protease inhibitors. The EBSS/collagenase solution was perfused through
the heart at 37®C for 15 -20 minutes or until the heart became uniformly lighter in color.
The heart was then perfused with BBSS mixed with 1% bovine serum albumin (BSA) for
10 minutes to wash away excess collagenase. HEPES buffer with 1% BSA was perfused
through the heart with increasing concentrations ofCaCb (0.25 and 0.5) for 10 minutes
each. This was followed by perfusion with HEPES buffer (without BSA) that had a
CaCl2 concentration of 1.0 mM for 10 minutes. The ventricle of the heart was removed,
placed in a small beaker containing HEPES buffer (1.0 mM CaCl2) in a water bath at
37”C, and diced into minute particles. The resulting myocyte suspension was filtered
with nylon gauze. The viability of the isolated cardiomyocytes was determined by
observation using a trinoculor microscope with a CCD camera. Only preparations
yielding cardiomyocytes that were 70% or better in viability (determined by their
elongated/rod shape and contractile movement) were used in further experimentation.
PHOSPHORYLATION OF RAT VENTRICULAR MYOFIBRILS
In situ phosphorylation of cardiomyocytes was performed using a modified
version of a previously published method (Jideama et al. 1996, 23277-23289). Isolated
cardiomyocytes were incubated (1.5 hour at 37° C) in phosphate free Dulbecco’s
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Modified Eagle’s Medium (DMEM) containing P. Following incubation, 1 mL aliquots
of the cells underwent additional incubation (10 minutes at 37° C) with an a-adrenergic
agonist (5 mM phenylephrine), a P-adrenergic agonist (100 nM isoproterenol), a PKC
activator (10 mM 12-10-tetradecanolyphorbol-13-acetae (TPA)), a Ca^^-dependent PKC
inhibitor (2.0 mM Go6976), a PKC inhibitor (600 nM chelerythrine chloride), or a P-
adrenergic antagonist (30 mM prazosin). Phenylephrine and isoproterenol were used to
indicate the involvement of the PKC and PKA pathways, respectively. After the various
treatments, the samples were pelleted and washed in buffer A solution (ImM PMSF, 100
pg/mL leupeptin, 100 pg/mL antipain, 100 pg/mL pepstatin A, 0.1 mM NaOV, 100 nM
CCA, and 5 mM EOTA), sonicated in buffer B solution (50 mM KH2PO4, 70 mM NaF, 5
mM EDTA, 1% Triton X-100,100 pg/mL leupeptin, 100 pg/mL antipain, 100 pg/mL
pepstatin A, and 100 nM CCA), iced for 30 minutes, and washed in modified buffer B
solution (without Triton X-100). The phosphorylation of samples was evaluated by SDS-
PAGE, autoradiography, densitometry (UN-SCAN-ITgeF** gel and graph digitalizing
software from the Silk Scientific Corporation (version 6.1)), and liquid scintillation
counts. Graphs and statistical analysis were formulated by using GraphPad Prism®
software (version 4.03).
DETERMINATION OF Ca^^-STIMULATED Mg ATPASE ACTIVITY AND
SENSITIVITY OF MYOFIBRILS
2+ 2-f-Ca -stimulatedMg ATPase activity was assayed according to published
methods (Jideama et al. 2006, 1-9; Noland et al. 1993, 53-65). The assay was carried out
at 30°C for 10 minutes in standard reaction mixtures (0.5 mL) containing 21 pg of rat
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cardiac myofibrils, 10 mM MOPS-KOH (pH 7.0), 4.1 mM Mg^ acetate, 2.1 mM [y-^V]
ATP (5-8 X 10^ cpm), 1 mM DTT, 1 mM EGTA, and 1.05 mM CaC^. CaC^^ when
present, was added as a mixture with EGTA and MOPS-KOH to provide a calculated free
2+
Ca -concentration of 0.01 -100 mM in the assay mixture. KCl was added to bring the
final ionic strength to 18 mM. The reactions were initiated by addition of radioactive [y-
32 32
P] ATP, terminated by addition of 10% charcoal suspension, and the released Pi was
determined as previously reported (Noland et al. 1995, 25445-25454). Stability constants
used in calculating the total concentration of reaction constituents required to give the
2+
necessary free Ca concentrations, were determined using previously published
procedures (Fabiato et al. 1988,469-495). The EC50 value for Ca^^ activation was
calculated from the equilibrium constant (K') according to formula: EC50 = (where
nh is the Hill coefficient). Graphs and statistical analysis were formulated by using
GraphPad Prism® software (version 4.03).
DETERMINATION OF VELOCITY OF MYOCYTE CONTRACTION
Surgical removal and perfusion of adult male Sprague-Dawley strain rat hearts
were conducted as mentioned in the prior section of the Materials and Methods. The
isolated cardiomyocytes were examined for adequate viability and incubated in
isoproterenol, phenylephrine, TPA, or chelerythrine chloride for 10 minutes at 37°C. The
treated myocytes were then placed on slides and observed using a trinocular microscope
with aNAVCO® CCD color camera and the Asymetic Digital Video Producer 5.0®
software program. The video of contracting myocytes was played back and stopped as
the cardiomyocyte reached its maximum contracted length and again stopped at its
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maximum relaxed length. The measurements were recorded along with their respective
times. These values (distance and time) were used to calculate the velocity of contracting
myocytes. The values were expressed as the mean of three different experiments.
Graphs and statistical analysis were formulated by using GraphPad Prism® software.
CHAPTER 4
RESULTS
IN VITRO SUBSTRATE SPECIFIC PHOSPHORYLATION OF RAT CARDIAC
MYOFIBRILS
Determining substrate specificity can serve as a vital parameter in understanding
the function of a particular enzyme in cardiac function. In order to determine the
substrate specificity of contractile component associated enzymes, rat ventricular
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myofibrils were phosphorylated by PKC isozymes (a, 5, 8, and Q and PKA using [y- P]
ATP. It was observed that PKC isozymes (a, 6, s, and Q and PKA expressed in adult rat
cardiomyofibrils showed distinct substrate specificities in phosphorylating contractile
components (Figure 1). Our results indicated that in intact rat ventricular
cardiomyofibrils: pan PKC (a mixture of the PKC isozymes) phosphorylated TnT 1.65
times more than Tnl; PKC-a phosphorylated TnT 1.62 times more than Tnl; PKC-5
phosphorylated Tnl 1.05 times more than TnT; PKC-s phosphorylated TnT 1.12 times
more than Tnl. PKC-^ phosphorylated TnT 1.78 times more than Tnl; and PKA
phosphorylated Tnl 12 times more than TnT. These results confirmed that PKC
isozymes and PKA display different substrate affinities in phosphorylating Tnl and TnT
in intact cardiac myofibrils. PKC-s phosphorylated proteins at 83 kDa, as determined by






Figure 1. Autoradiograph showing substrate specificities of PKC isozymes and PKA
for in vitro phosphorylation of adult rat cardiomyofibrillar proteins. The intergrated
density values were (1) 30600, (2) 33000, (3) 22200, (4) 34300, (5) 19200, (6) 1200, (7)
18600, (8) 20400, (9) 21200, (10) 30600, (11) 10800, and (12) 14400.
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weight is approximately the same as that of this isozyme. Therefore, PKC-e is most
likely responsible for the autophosphorylation of PKC.
CONCENTRATION-DEPENDENT PHOSPHORYLATION OF RAT CARDIAC
MYOFIBRILS
Certain conditions must be taken into consideration when investigating with the
use of kinase enzymes. Enzymatic activity may be altered by conditions such as the
temperature and pH of the environment, as well as the enzyme to substrate concentration
ratio. Previous reports (Noland et al. 1995,25445-25454) have indicated that in
reconstituted troponin (Tn), PKC-a phosphorylated Tnl more than TnT at concentrations
less than 20 pM. At concentrations above 20 pM, Tnl exhibits substrate inhibition to this
isozyme. Therefore, in support of specific aim 1 (characterization of the in vitro
phosphorylation of contractile proteins (Tnl and TnT) in adult rat cardiomyofibrils by
PKC isozymes and PKA), it was of interest to further characterize the biochemical
modifications of contractile components (Tnl and TnT) associated with the
concentration-dependent in vitro phosphorylation of intact adult rat cardiomyofibrils
using PKC-a. Concentration-dependent phosphorylation of rat cardiac myofibrils by
PKC-a showed that Tnl is phosphorylated more than TnT at lower substrate (myofibril)
concentrations of (Figure 2), as confirmed by densitometry. Contrarily, at higher
substrate concentrations, TnT is phosphorylated more than Tnl. This implies that PKC-a
phosphorylation of the myofibrils shows substrate inhibition ofTnl at higher substrate
concentrations. This Tnl substrate inhibition ofPKC-a (Figure 2) is believed to have a




Figure 2. Concentration-dependent phosphorylation by PKC-a showing substrate
inhibition of Tnl in rat ventricular myofibrils. The intergrated density values were (1)
4914, (2) 5460, (3) 7644, (4) 7644, (5) 8736, (6) 7644, (7) 7098, and (8) 6006.
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discussion component of this document.
/iV5/ri/PHOSPHORYLATION OF RAT CARDIOMYOCYTES
One of the primary goals of biomedical research is for one’s research to eventually be
examined in vivo (within the living organism). Before this level of research is reached
there are usually intermediate sets of experimentation conducted in situ (within a living
isolated cellular environment). Therefore, it was of interest to compare results that were
obtained by way of the in vitro (within an artificial environment) experiments to results
that resulted from in situ experimentation. In situ phosphorylation of isolated adult rat
cardiomyocytes was used to substantiate the in vitro experiments, which indicated site-
specific phosphorylation of cardiomyocytes. One-milliliter aliquots of isolated
cardiomyocytes (Figure 3) incubated (1.5 hours) with were subjected to further
incubations (10 minutes) with phenylephrine (a-adrenergic agonist), isoproterenol (P-
adrenergic agonist), or 12-10-tetradecanolyphorbol-13-acetae (TPA) (diacylglycerol-
dependent PKC activator). The identity of the phosphorylated proteins was based on the
comparison of their relative migration with a standard protein molecular weight, and
confirmed by autoradiography and densitometry. The autoradiograph of the SDS-PAGE
gel indicated that overall, TnT was phosphorylated to a greater extent than Tnl (Figures
4, 5a, and 5b; Table 1). It was observed that when the signaling pathway ofPKC (a-
adrenergic signaling transduction pathway) was stimulated with phenylephrine, TnT’s
phosphorylation was increased (1.12 fold increase (1.60 x 10^ intensity units (iu))), while
Tnl phosphorylation also increased (1.19 fold (0.64 x 10^ iu)), as compared to respective
controls (1.43 x 10^ iu for control TnT and 0.54 x 10^ iu for control Tnl) (Figures 4, 5a,
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Figure 3. Isolated adult rat cardiomyocytes at 200x. Only preparations displaying
70% viability or better were used in further experimentation.
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and 5b; Table 1). The results obtained from in situ phosphorylation due to the induction
ofPKA by the beta-adrenergic pathway using isoproterenol indicated a decrease (1.30
fold decrease (1.10 x 10^ iu)) in TnT phosphorylation, and the greatest phosphorylation
increase ofTnl among the treatments (2.07 fold increase (1.12 x 10^ iu)). The activation
of diacylglycerol (DAG)-dependent PKC isozymes by TPA yielded an approximately
1.05 fold increase in TnT phosphorylation (1.50 x 10^ iu) and a 1.17 fold decrease in the
phosphorylation ofTnl (0.46 x 10^ iu), as compared to the respective controls.
Additionally, it was of interest to examine the effect of inhibiting Ca -dependent
PKC isozymes, all PKC isozymes, or the a-adrenergic pathway. Therefore, isolated P-
myocytes were incubated for 10 minutes with G66976 (Ca^^-dependent PKC inhibitor),
chelerythrine chloride (nonselective PKC inhibitor), or prazosin (a-adrenergic
antagonist). Myocytes treated with G66976 showed a slight increase of 1.06 fold (0.57 x
10^ iu) in the phosphorylation ofTnl, as well as a slight increase of 1.08 fold (1.54 x 10^
iu) in the phosphorylation ofTnT (Figures 4, 5a, and 5b; Table 1). Myocytes treated with
chelerythrine chloride showed a nearly significant decrease of 1.36 fold (1.05 x 10* iu) in
the phosphorylation ofTnT, and a slight increase of 1.19 fold (0.64 x 10* iu) in the
phosphorylation ofTnl. Myocytes treated with prazosin showed a significant decrease of
1.55 fold (0.92 X 10* iu) in the phosphorylation ofTnT, and a moderate, though non¬




Figure 4. Autoradiograph of the in situ phosphorylation of adult rat cardiomyocyte
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contractile proteins. Aliquots of isolated cardiomyocytes incubated with P, were
subjected to further incubations with agonists, antagonists, activators, or inhibitors of
PKC or PKA. The samples were subjected to SDS-PAGE, followed by autoradiography








Figure 5a. Densitometry values for the autoradiogragh of the in situ
phosphorylation of adult rat cardiomyocyte contractile protein, TnT (Figure 4).
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Aliquots of isolated cardiomyocytes incubated with P, were subjected to further
incubations with isoproterenol, phenylephrine, or TPA. The samples were subjected to
SDS-PAGE, followed by autoradiography and densitometry (measured in intensity units).
The values were expressed as the mean of three different experiments. The * indicates
values significantly different from the control.
27
*
Figure 5b. Densitometry values for the autoradiogragh of the in situ
phosphorylation of adult rat cardiomyocyte contractile protein, Tnl (Figure 4).
Aliquots of isolated cardiomyocytes incubated with P, were subjected to further
incubations with isoproterenol, phenylephrine, or TPA. The samples were subjected to
SDS-PAGE, followed by autoradiography and densitometry (measured in intensity units).
The values were expressed as the mean of three different experiments. The * indicates
values significantly different from the control.
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Table 1. Densitometry values for the autoradiogragh of the in situ phosphorylation





TnT 1.43x105±0.21 1.54xl05± 0.23 1.05xl05±0.17 1.10<105±0.17
Tnl 0.54xl05±0.05 0.57x105±0.07 0.64x105±0.04 1.12x105±0.14
Control
(Unti-eatedl) Pheiiylopliriiie TPA Prazosin
TnT 1.43 >105±0.21 1.60xl05±0.23 1.51> 105 ±0.22 0.92 >105 ±0.14
Tul 0.54k105± 0.05 0.64 xl05± 0.05 0.46x105±0.05 0.46x105 ±0.05
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Aliquots of isolated cardiomyocytes incubated with P, were subjected to further
incubations with agonists, antagonists, activators, or inhibitors ofPKC or PKA. The
samples were subjected to SDS-PAGE, followed by autoradiography and densitometry
(measured in intensity units). The values were expressed as the mean of three different
experiments.
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Ca^^-STIMULATED Mg ^^ATPASE ACTIVITY AND SENSITIVITY OF
RAT CARDIAC MYOFIBRILS
As previously discussed, the troponin complex regulates the contraction of
cardiac muscle. One of the most important steps in contraction involves the binding of
calcium to the TnC component of the troponin complex. The more sensitive the complex
is to calcium, the more likely contraction is to occur. Additionally, contraction results
from the interaction of actin and myosin, whereby ATP (bound to the myosin head) is
hydrolyzed by Mg ^^ATPase of the actin molecule. Therefore, it is reasonable to
associate the level Mg ^"^ATPase activity with the amount of contraction that occurs.
Phosphorylation of contractile components by different kinases is likely to alter the level
ofCa^’^sensitivity and Mg ^^ATPase activity. With this in mind, the physiological
relevance of the phosphorylation ofventricular cardiomyofibrils by PKC isozymes (a, 5,
8, and Q and PKA was examined (Figure 6). The results were summarized (Table 2) in
order to determine the effects ofPKC isozymes and PKA phosphorylation on
, 2"F 2*^
myofibnllar Mg ATPase activity and Ca sensitivity. In general, it was found that
phosphorylation of rat ventricular cardiomyofibrils by PKC isozymes (a, 6, s, and Q and
2*F 2"b
PKA decreased myofibrillar Ca -stimulated Mg ATPase maximal activity (Figure 6).
2+
However, they have variable effects onmyofibrillar Ca sensitivities (Table 2).
Phosphorylation of rat cardiac myofibrils by PKC-6, PKC-s, and PKA fairly decreased
2+
myofibrillar Ca sensitivity (5.0 pM, 5.3 pM, 5.0 pM, respectively), when compared to
the control (no enzyme) (3.2 pM). Whereas PKC-a phosphorylation of cardiac
2+
myofibrils greatly decreased Ca sensitivity (16.5 pM), phosphorylation of these
30
2+
cardiomyofibrils by PKC-^ sharply increased Ca sensitivity (1.9 pM). Therefore, PKC-
a has implications to be functionally antagonistic to PKC-^ in cardiac physiology.
31




















Figure 6. Effects of in vitro phosphorylation by PKC isozymes and PKA on Ca
sensitivity and Mg^^ATPase activity in rat cardiomyofibrils. Phosphorylated and
unphosphorylated myofibrils were incubated at 37°C for 10 minutes in the presence of
varying Ca^"^ concentrations (0.01-100 mM). The findings were confirmed in another set
of experiments.
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Table 2. Kinetic data for Ca^^timulated Mg^^ATPase activity and Ca^^sensitivity






Enzyme % Control pM
None (Control) 100 3.2 + 0.12
pan PKC 85 3.3 ± 0.43
PKC-a 88 16.5 ± 0.35^
PKC-6 82 5.0 ±0.15^
PKC-8 84 5.3 ± 0.47^
PKC-C 96 1.9±0.13^
PKA 91 5.0 + 0.11^
^ indicates values significantly different from the control (Student’s Mest, p < 0.05).
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DETERMINATION OF/N5/ri7MECHANICAL CHANGES OF
CARDIOMYOCYTES
Another point of interest was to observe the effect of phosphorylation on the rate
ofmyocytic contraction. In continuation with the in situ studies, alterations in
cardiomyocyte contraction associated with the stimulation or inhibition of the activity of
PKC isozymes and PKA were evaluated by incubating isolated, viable cardiomyocytes in
isoproterenol, phenylephrine, TPA, or chelerythrine chloride. The incubations were
followed by observation using a trinocular microscope with a CCD camera that fed the
video into a digital video software program, thus recording contractile movement (Figure
7). The mean velocities of cardiomyoc5des treated with isoproterenol and phenylephrine
were both higher (6.00x10'^ m/s and 3.47x10’^ m/s, respectively) than the control
(untreated) cardiomyocytes, which had a mean velocity of 2.60x 10‘^ m/s (Figure 8; Table
3). Cardiomyocytes treated with chelerythrine chloride displayed a mean velocity that
was higher than the control velocity, however the increase in velocity associated with this
treatment was shown to be non-significant. Contrarily, cardiomyocytes treated with TPA
displayed a reduction (1.67x10'^ m/s) in the mean velocity of contracting cardiomyocytes
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Figure T.Visualization of relaxed and contracted cardiomyocytes treated with
isoproterenol, phenylephrine, TPA, or chelerythrine chloride. Isolated myocytes
were incubated in different treatments and observed using a CCD camera on a trinocular
microscope. The video of contracting myocytes was replayed while the time and
distances between relaxed and contracted phases were obtained.
35
Table 3. Velocity of contracting isolated myocytes treated with isoproterenol,






ir7x 10^*±017 217xiO»±0?3 1.00 k 10* ±029 183 k 10* ±060 1.50 k 10*±029
Mean 0 e56 ± 0 05 0713 ±018 057S±0,06 0 390 ±001 0560 ±01$
Mnaoi
260 k 032 347k1O»±0:»» 167 k 10* ±0 22 600 k 10* ±087 289 k 10* ±048
The video of contracting cardiomyocytes, subjected to different treatments, was used to
measure the relaxed length, contracted length, and contraction time. These values were







Figure 8. Velocity of contracting myocytes treated with isoproterenol,
phenylephrine, TPA, or chelerythrine chloride. Isolated myocytes were incubated in
different treatments and placed on slides to observe contractile movement using a video
camera on a trinocular microscope. The video of contracting myocytes was played back
while measurements were taken to calculate the velocity ofmyocytic contraction. The
values were expressed as the mean of three different experiments. The * indicates values
significantly different from the control.
CHAPTER 5
DISCUSSION
IN VITRO SITE SPECIFIC PHOSPHORYLATION OF CONTRACTILE
PROTEINS BY PKC ISOZYMES AND PKA
This study presented evidence that PKC isozymes (a, 6, s, and Q and PKA
displayed distinct substrate and functional specificities in phosphorylating adult male rat
ventricularmyofibrils. It is important to note that in intact adult rat ventricularmyofibrils
(21 pg used as substrate), PKC-a phosphorylated TnT more than Tnl and caused a
2+
drastic decrease in myofibrillar Ca sensitivity. This finding revealed that
phosphorylation of intact ventricularmyofibrils by PKC-a may have a dual function in
regulating cardiac physiology. The dual functions are prompted by (a) the decrease in
myofibrillar calcium sensitivity and (b) the negative feedback inhibition caused by Tnl
substrate inhibition. On the other hand, PKC-i^ phosphorylated mostly TnT in the cardiac
2+
myofibrils and sharply increased myofibrillar Ca sensitivity. Therefore, it is very
important to address the physiological parameters of these isozymes in regulating cardiac
function.
It has been previously reported (Noland et al. 1995,25445-25454) that in
reconstituted troponin (Tn), PKC-a phosphorylated Tnl more than TnT at concentrations
less than 20 pM. At concentrations above 20 pM, Tnl exhibits substrate inhibition to this
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isozyme. These findings confirmed the above in intact ventricular myofibrils and further
delineate specific functions of these isozymes.
INSITU SITE SPECIFIC PHOSPHORYLATION OF CONTRACTILE
PROTEINS BY PKC ISOZYMES AND PKA
It has been previously reported that the role ofphosphorylation in cardiac muscle
physiology was to regulate Ca^'^-stimulated Mg^’^ATPase activities and calcium
sensitivity (Noland et al. 1996,14923-14931; Jideamaet al. 1996,23277-23289). The
correlations between in situ phosphorylation ofadult rat cardiomyocytes and its
contractile velocity are unclear. The in situ phosphorylation experiments performed in
this study were able to support the in vitro study results by displaying continuity in the
site-specific phosphorylation patterns. Figure 1 showed that PKA (activated by the P-
adrenergic pathway) predominately phosphorylates the Tnl subunit. Figure 4 displayed
that when treated with isoproterenol (P-adrenergic agonist), cardiomyocytes show
increased phosphorylation on the Tnl subunit. Phenylephrine (a-adrenergic agonist)
showed similar supporting results by causing an increase in the phosphorylation of TnT
and Tnl (Figures 4, 5a, and 5b; Table 1), which have been indicated by Figure 1 to be
sites for PKC isozymes (beneficiaries of the a-adrenergic pathway). The use of
prazosine, an a-adrenergic antagonist, showed an expected decrease in the
phosphorylation ofTnT and Tnl (Figures 4, 5a, and 5b; Table 1), indicating that the a-
and P- adrenergic pathways play a role in the phosphorylation of contractile components
in adult rat cardiomyocytes.
Treatments involving TPA, activator of diacylglycerol dependent PKC isozymes.
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accordingly showed an increase in Tnl and TnT phosphorylation. Chelerythrine
chloride treated cardiomyocytes displayed decreased phosphorylation of TnT and Tnl,
which was expected due to its ability to non-selectively inhibit PKC isozymes. G66976
treated cardiomyocytes displayed a minor increase in TnT and Tnl phosphorylation.
Although Gd6976 is an inhibitor ofCa^'^-dependent PKC isozymes (a, Pj, Pjj, and
y), the remaining active PKC isozymes present in the cardiomyocytes (5, e, and Q are
still capable ofphosphorylating the troponin subunits. The absence of the Ca^^-
dependent PKC isozymes may serve to decrease the competition for the phosphorylation
of the subunits, which may therefore result in the increased phosphorylation.
FUNCTIONAL SIGNIFICANCES OF CONTRACTILE PROTEIN
PHOSPHORYLATION BY PKC ISOZYMES AND PKA
It is most likely that PKC-i^ phosphorylation ofTnT in cardiac myofibrils occurs
at the onset ofmuscle contraction, when the extracellular calcium is minimal. Sharp
increases in calcium ion sensitivity are needed to catalyze the chemical reactions
necessary to promote the sliding of actin and myosin along one another, also known as
muscle contraction. These chemical reactions include: (1) phosphorylation ofTnl and
TnT by PKC isozymes, (2) calcium release and binding to TnC, and (3) the detachment
of tropomyosin from TnT. Since PKC-^ phosphorylation of cardiac myofibrils increased
2"b
Ca sensitivity, its function may be linked to the initiation ofmuscle contraction. At the
resting potential of cardiac muscle, tropomyosin binds to TnT and calcium is stored in the
2+
sarcoplasmic reticulum. During action potential, Ca is released and binds to TnC
causing the detachment of tropomyosin from TnT and initiating muscle contraction. The
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release ofcalcium from the sarcoplasmic reticulum and its binding to TnC can be
2+
associated with the increase in Ca -sensitivity, as indicated by the differences in the
2+
Ca -sensitivity of unphosphorylated cardiomyofibrils (3.2 pM) and the PKC-<^
phosphorylated cardiomyofibrils (1.9 pM) (Table 2). The increase in calcium sensitivity
is most likely due to PKC-i^ phosphorylation of the cardiomyofibril proteins, since
2+
smaller quantities ofCa are required for reaching maximum activity.
Data from this study also explicitly showed that by using 21 pg of cardiac
myofibrils as substrate, PKC-a phosphorylated TnT more than Tnl, suggesting the dual
functions ofPKC-a phosphorylation of the myofibrils, as mentioned above. These
functions are: (a) negative feedback control of cardiac muscle contraction due to substrate
2+
inhibition ofTnl and (b) a decrease in Ca sensitivity, as indicated by the differences in
unphosphorylated cardiomyofibrils (3.2 pM) and PKC-a phosphorylated
cardiomyofibrils (16.5 pM) (Table 2). In the present study, the Tnl substrate inhibition is
likely to function as a switch mechanism from optimal cardiac muscle contraction to a
relaxation phase. The observed result ofPKC-a phosphorylation decreasing myofibrillar
2+ 2+
Ca sensitivity (Table 2) suggests that functionally, PKC-a is activated during large Ca
2+
influx into the sarcolemma. Specifically, this large Ca influx comes from the T-tubules,
2+
which releases large quantities ofCa directly into the extracellular fluid of the cardiac
muscle. These calciiun ions are released during the action potential and are needed for
maximal contraction. This suggests that Tnl substrate inhibition occurs at the end of
cardiac muscle contraction, when the influx of calcium ions into the muscle fiber is
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maximal. In order to avoid hyper-contractility, calcium is pumped back into the
sarcoplasmic reticulum and T-tubules, therefore, stopping contraction. The ability of
PKC-a phosphorylation to decrease calcium sensitivity and to cause Tnl substrate
inhibition suggests that this isozyme is a calcium regulator in cardiac muscle
contractility. It also suggests that it initiates the inhibitory effect ofTnl, and functions to
terminate each cardiac muscle contractile phase by causing substrate inhibition of the
inhibitory subunit, Tnl.
While PKC-a phosphorylation proposes to function as a terminator of each
cardiac contractile phase, PKC-(!^ phosphorylation of ventricular myofibrils is likely to
initiate cardiac muscle contraction. Since PKC-^ phosphorylated mostly TnT, the
binding site of tropomyosin during the resting potential (non-contracting phase), it is
suggested that its mechanism of action results in the conformational change, which is
thought to tug on the tropomyosin molecule leading to its release from TnT of the actin
filament. Also, phosphorylation ofTnT by PKC-^ increased calcium sensitivity, making
calcium available for binding at TnC. This calcium release and binding to TnC is
believed to initiate cardiac muscle contraction, implicating PKC-<^ to initiation of cardiac
muscle contraction. Contrarily, PKC-a, which phosphorylated Tnl more than TnT at low
concentrations and exhibits substrate inhibition ofTnl at high concentrations, reduced
calcium sensitivity probably when TnC, the calcium-binding site, is fully saturated. This
implies that PKC-a phosphorylation inhibits further release ofcalcium from
sarcoplasmic reticulum and T-tubules and its binding to TnC, therefore, terminating
cardiac muscle contraction. It is most likely that substrate inhibition ofTnl, which occurs
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as a result ofPKG-a phosphorylation, occurs concurrently with the decrease in calcium
level. Substrate inhibition ofTnl (the binding site for actin) phosphorylation by PKC-a
may be the mechanism necessary for the inhibition of the actin filament by troponin-
tropomyosin complex. In relaxed cardiac muscle, the active sites of actin filament are
physically covered by the troponin-tropomyosin complex, which prevents the attachment
of the heads of the myosin filaments. Therefore, PKC-a phosphorylation ofTnl at low
concentrations, when Tnl is phosphorylated more than TnT, and PKC-^ phosphorylation
ofTnT, which increases calcium sensitivity, may be implicated to the physiological
mechanism needed for the removal of troponin-tropomyosin complex from the active
sites of actin filament. On the other hand, decrease in calcium sensitivity and substrate
inhibition ofTnl phosphorylation by PKC-a may be essential parameters for troponin-
tropomyosin complex binding to the active sites of the actin filament causing the muscle
to relax.
MECHANICAL EFFECTS ON CARDIOMYOCYTE PHYSIOLOGY
ASSOCIATED WITH PKC ISOZYMES AND PKA
This study also determined the effects of inducing the activation ofPKC and PKA
on the cardiomyocytic velocities. The correlation between in situ phosphorylation and
contractile velocities ofadult rat cardiomyocytes treated with a- and P- adrenergic
signaling pathway agonists (phenylephrine and isoproterenol, respectively) showed some
significant differences in the contractile velocities of the cardiomyocytes. Stimulation of
each pathway increased the contractile velocity over 25%, when compared to the control
(imtreated) myocytes. This suggests that though the pathways are specific in the
43
activation of these enzymes, they both have similar effects on the mechanical properties
of the contractile proteins.
As previously mentioned, the in vitro studies revealed that PKA shows substrate
specificity in phosphorylating the troponin ATPase inhibitory subunit (Tnl), while
the PKC isozymes phosphorylate TnT preferably higher than Tnl. Treatment with the
phorbol ester (TPA) resulted in a decrease in contractile velocity. TPA is commonly
used as an activator ofPKC. TPA is a non-hydrolysable, non-physiological analogue
structurally similar to diacylglycerol that, unlike diacylglycerol, it is not readily degraded
and continues to activate diacylglycerol dependent isozymes ofPKC (a, pi, pn, 5, and s).
The decrease in contractile velocity after TPA treatment (Figure 8; Table 3) may be a
result of increased phosphorylation of the TnT and the decreased phosphorylation in the
Tnl component of the troponin complex. Furthermore, chelerythrine chloride was used to
evaluate the effect ofPKC inhibition. It was observed that chelerythrine chloride treated
cardiomyocytes (which caused a decrease in TnT phosphorylation and an increase in Tnl
phosphorylation) displayed a velocity almost twice that ofTPA treated cardiomyocytes.
This suggests that the PKC isozymes may display a regulatory role in keeping myocytes
contraction from reaching high velocities that can over work the heart, leading to cardiac
arrest. The P-adrenergic (PKA activation pathway) influenced in situ phosphorylation of
Tnl was much more than that of the control, phenylephrine, and TPA treated
cardiomyocytes, while its phosphorylation ofTnT was close to being significantly less
than the control. Interestingly, the contractile velocities of these P-adrenergic influenced
in situ phosphorylated cardiomyocytes were the highest among the other treated
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cardiomyocytes.
The lack of significant differences in the in situ phosphorylation ofTnT (Figures
5a and 5b) suggests that the in situ phosphorylation of the Tnl component has a
distinguished effect on increasing the contractile velocity of the cardiomyocytes. This
data cooperatively suggests that the contractile velocity of cardiomyocytes increases with
the phosphorylation intensity ofTnl and decreases with the phosphorylation intensity of
TnT.
SUMMARY AND FUTURE STUDIES
The data from this study has collectively revealed that the phosphorylation of
adult rat cardiomyocytes by various PKC isozymes and PKA have (a) specific substrates
on cardiomyofibrils and (b) display alternating effects on the physiological aspects of
cardiomyocyte function. It is anticipated that future experiments will make use of this
data by attempting to manipulate the contraction of cardiomyocytes in in vivo
experiments. These experiments would potentially involve the use ofhypertensive rats,
whereby the goal would be to alter the contractile patterns of the heart by manipulating
the involvement of the adrenergic pathways.
Previously, it has been reported that PKA phosphorylates Tnl at serine 23/24
(Noland et al. 1996,14923-14931). It therefore becomes apparent from this data that the
contractile velocity of the cardiac muscle may be optimum with the amino acid terminal
end phosphorylation ofTnl at the serine 23/24 phosphorylation site, which is
characterized by PKA. Phosphorylation alone is not as important as the type and location
ofphosphorylation. PKC and PKA phosphorylate at different sites within a protein
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sequence. Further studies may reveal the precise fimction of these phosphorylation sites
by deletion or addition of amino acids within these sites, which may lead to a better
understanding of the roles each kinase has in cardiomyopathies.
Future studies will also involve the evaluation of an additional enzyme, myosin
light chain kinase (MLCK), and its substrate, myosin light chain 2 (MLC2). In addition
to Tnl and TnT in the thin filament, phosphorylation ofMLC2 in the thick filament is
also involved in the regulation ofmuscle contraction. Abnormal cardiac structure and
function in mice has been linked to non-phosphorylatable regulatory MLC2 (Sanbe et al.
1999,21085-21094). The 20 kDa MLC2 in vertebrate non-muscle and muscle cells is
phosphorylated by a specific Ca^Vcalmodulin-dependent MLCK (Solero 2000, 173;
Sellers et al. 1987, 381-418). MLCK mediated phosphorylation in smooth muscle is
associated with a greater than 100-fold (Sellers 1985, 15815-15819) increase in actin-
■y,
activated Mg ATPase activity ofmyosin and is a primary mechanism for initiation of
contraction. Furthermore, MLC2 is also a substrate for PKC. PKC incorporates
phosphate into smooth muscle or non-muscle MLC2 in vitro and in situ at sites that are
distinct from the MLCK sites (Jideama et al. 2006,1-9; Ludowyke et al. 1989,12492-
12501). PKC-mediated phosphorylation has also been shown to inhibit increases in
Mg^"^ATPase activity associated with phosphorylation by MLCK (Bogatcheva et al.
2003, L415 - L426; Nishikawa et al. 1984, 8808-8814). The physiological significance
of this phosphorylation has not been clearly defined. Therefore, it is hoped that these
future studies may be used to bring more understanding to the collective role of kinases
and their substrates in the regulation of contractile function.
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